Meeting
2023 ASCO Genitourinary Cancers Symposium
Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma—A phase 1, open-label, pharmacokinetic, safety and tolerability study.
Authors
Tomoko Hirohashi
Pfizer, Inc., New York, NY
Tomoko Hirohashi , Joseph Thaddeus Beck , Jessica Dreger McDermott , James L. Abbruzzese , Toshihiko Doi , Kim Ingram , Ruifeng Li , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04458259
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS743)
DOI
10.1200/JCO.2023.41.6_suppl.TPS743
Abstract #
TPS743
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott
Poster
2021 ASCO Annual Meeting
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
First Author: Vivek Subbiah
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
First Author: Daniel E. Castellano
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors (ICIs) in patients (pts) with inoperable locally advanced or metastatic solid tumors: Description of genitourinary (GU) expansion cohorts.
First Author: Manish Sharma